211 related articles for article (PubMed ID: 31328883)
1. An autocrine ActivinB mechanism drives TGFβ/Activin signaling in Group 3 medulloblastoma.
Morabito M; Larcher M; Cavalli FM; Foray C; Forget A; Mirabal-Ortega L; Andrianteranagna M; Druillennec S; Garancher A; Masliah-Planchon J; Leboucher S; Debalkew A; Raso A; Delattre O; Puget S; Doz F; Taylor MD; Ayrault O; Bourdeaut F; Eychène A; Pouponnot C
EMBO Mol Med; 2019 Aug; 11(8):e9830. PubMed ID: 31328883
[TBL] [Abstract][Full Text] [Related]
2. Canonical TGF-β pathway activity is a predictor of SHH-driven medulloblastoma survival and delineates putative precursors in cerebellar development.
Aref D; Moffatt CJ; Agnihotri S; Ramaswamy V; Dubuc AM; Northcott PA; Taylor MD; Perry A; Olson JM; Eberhart CG; Croul SE
Brain Pathol; 2013 Mar; 23(2):178-91. PubMed ID: 22966790
[TBL] [Abstract][Full Text] [Related]
3. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.
Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X
Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of CRX, a Group 3-specific oncogenic transcription factor, inhibits TGF-β/activin signaling in medulloblastoma cells.
Masurkar SA; Deogharkar A; Bharambe HS; Shirsat NV
Biochem Biophys Res Commun; 2021 Sep; 568():76-82. PubMed ID: 34192607
[TBL] [Abstract][Full Text] [Related]
5. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.
Faria CC; Golbourn BJ; Dubuc AM; Remke M; Diaz RJ; Agnihotri S; Luck A; Sabha N; Olsen S; Wu X; Garzia L; Ramaswamy V; Mack SC; Wang X; Leadley M; Reynaud D; Ermini L; Post M; Northcott PA; Pfister SM; Croul SE; Kool M; Korshunov A; Smith CA; Taylor MD; Rutka JT
Cancer Res; 2015 Jan; 75(1):134-46. PubMed ID: 25391241
[TBL] [Abstract][Full Text] [Related]
6. A Novel TGFβ Trap Blocks Chemotherapeutics-Induced TGFβ1 Signaling and Enhances Their Anticancer Activity in Gynecologic Cancers.
Zhu H; Gu X; Xia L; Zhou Y; Bouamar H; Yang J; Ding X; Zwieb C; Zhang J; Hinck AP; Sun LZ; Zhu X
Clin Cancer Res; 2018 Jun; 24(12):2780-2793. PubMed ID: 29549162
[No Abstract] [Full Text] [Related]
7. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of HMGA1 deregulates tumor growth via cdc25A and alters migration/invasion through a cdc25A-independent pathway in medulloblastoma.
Lau KM; Chan QK; Pang JC; Ma FM; Li KK; Yeung WW; Cheng AS; Feng H; Chung NY; Li HM; Zhou L; Wang Y; Mao Y; Ng HK
Acta Neuropathol; 2012 Apr; 123(4):553-71. PubMed ID: 22249617
[TBL] [Abstract][Full Text] [Related]
9. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
[TBL] [Abstract][Full Text] [Related]
10. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
[TBL] [Abstract][Full Text] [Related]
11. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
[TBL] [Abstract][Full Text] [Related]
12. Pluripotency gene expression and growth control in cultures of peripheral blood monocytes during their conversion into programmable cells of monocytic origin (PCMO): evidence for a regulatory role of autocrine activin and TGF-β.
Ungefroren H; Hyder A; Hinz H; Groth S; Lange H; El-Sayed KM; Ehnert S; Nüssler AK; Fändrich F; Gieseler F
PLoS One; 2015; 10(2):e0118097. PubMed ID: 25707005
[TBL] [Abstract][Full Text] [Related]
13. ASC deficiency suppresses proliferation and prevents medulloblastoma incidence.
Knight ER; Patel EY; Flowers CA; Crowther AJ; Ting JP; Miller CR; Gershon TR; Deshmukh M
Oncogene; 2015 Jan; 34(3):394-402. PubMed ID: 24469054
[TBL] [Abstract][Full Text] [Related]
14. PUMC-MB1 is a novel group 3 medulloblastoma preclinical model, sensitive to PI3K/mTOR dual inhibitor.
Wang S; Zhang D; Wang J; Peng X; Sun H; Ji Y; Yang Z; Bian X; Hou Y; Ge M; Liu Y
J Neurooncol; 2024 May; 168(1):139-149. PubMed ID: 38662151
[TBL] [Abstract][Full Text] [Related]
15. Real-time sensing of MAPK signaling in medulloblastoma cells reveals cellular evasion mechanism counteracting dasatinib blockade of ERK activation during invasion.
Schönholzer MT; Migliavacca J; Alvarez E; Santhana Kumar K; Neve A; Gries A; Ma M; Grotzer MA; Baumgartner M
Neoplasia; 2020 Oct; 22(10):470-483. PubMed ID: 32818841
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo.
Spiller SE; Logsdon NJ; Deckard LA; Sontheimer H
BMC Cancer; 2011 Apr; 11():136. PubMed ID: 21492457
[TBL] [Abstract][Full Text] [Related]
17. Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma.
Gordon RE; Zhang L; Peri S; Kuo YM; Du F; Egleston BL; Ng JMY; Andrews AJ; Astsaturov I; Curran T; Yang ZJ
Clin Cancer Res; 2018 Mar; 24(6):1375-1388. PubMed ID: 29437795
[No Abstract] [Full Text] [Related]
18. RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via JNK-dependent but p53-independent mechanism.
Azatyan A; Gallo-Oller G; Diao Y; Selivanova G; Johnsen JI; Zaphiropoulos PG
Cancer Lett; 2019 Feb; 442():341-350. PubMed ID: 30447254
[TBL] [Abstract][Full Text] [Related]
19. A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma.
Wang F; Remke M; Bhat K; Wong ET; Zhou S; Ramaswamy V; Dubuc A; Fonkem E; Salem S; Zhang H; Hsieh TC; O'Rourke ST; Wu L; Li DW; Hawkins C; Kohane IS; Wu JM; Wu M; Taylor MD; Wu E
Oncotarget; 2015 Feb; 6(5):2709-24. PubMed ID: 25576913
[TBL] [Abstract][Full Text] [Related]
20. BMI1 is a therapeutic target in recurrent medulloblastoma.
Bakhshinyan D; Venugopal C; Adile AA; Garg N; Manoranjan B; Hallett R; Wang X; Mahendram S; Vora P; Vijayakumar T; Subapanditha M; Singh M; Kameda-Smith MM; Qazi M; McFarlane N; Mann A; Ajani OA; Yarascavitch B; Ramaswamy V; Farooq H; Morrissy S; Cao L; Sydorenko N; Baiazitov R; Du W; Sheedy J; Weetall M; Moon YC; Lee CS; Kwiecien JM; Delaney KH; Doble B; Cho YJ; Mitra S; Kaplan D; Taylor MD; Davis TW; Singh SK
Oncogene; 2019 Mar; 38(10):1702-1716. PubMed ID: 30348991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
